In ₹ Crore except Per Share Latest Annual	MANKIND FY26	SUNPHARMA FY26	CIPLA FY26	TORNTPHARM FY26	Peer Average
Valuation — at last close
P/E	53.72×	36.77×	◆ 28.43×	71.29×	45.50× +18%
P/B	6.31×	5.05×	◆ 3.20×	18.39×	8.88× -29%
EV/EBITDA	29.67×	22.19×	◆ 17.28×	38.65×	26.04× +14%
Market Cap	₹1.03L Cr	₹4.22L Cr	₹1.10L Cr	₹1.54L Cr	₹2.29L Cr -55%
Growth
Revenue CAGR 3Y	◆ 17.73%	10.03%	7.37%	13.27%	10.22% +73%
Revenue CAGR 5Y	—	11.78%	8.01%	◆ 11.80%	10.53%
Net Income CAGR 3Y	13.96%	10.57%	10.88%	◆ 19.75%	13.73% +2%
Revenue YoY (latest Q)	17.33%	10.46%	-2.44%	◆ 50.79%	19.60% -12%
Net Income YoY (latest Q)	◆ 37.67%	26.53%	-37.08%	-9.64%	-6.73% +660%
Profitability
EBITDA Margin	25.34%	30.33%	20.89%	◆ 32.61%	27.94% -9%
Net Income Margin	13.57%	◆ 19.69%	13.71%	15.29%	16.23% -16%
Return on Common Equity	12.49%	14.74%	11.82%	◆ 27.07%	17.88% -30%
Return on Capital Employed	12.51%	◆ 18.48%	13.87%	14.88%	15.74% -21%
Return on Assets	6.94%	◆ 11.46%	9.67%	7.21%	9.45% -27%
Credit & Quality
Total Debt/Equity	0.38×	0.05×	◆ 0.01×	0.84×	0.30× +27%
Interest Coverage	4.27×	43.65×	◆ 85.90×	8.94×	46.16× -91%
Scale — latest FY
Revenue / Total Income	₹14,278 Cr	₹58,462 Cr	₹28,163 Cr	₹13,980 Cr	₹33,535 Cr -57%
Net Income	₹1,938 Cr	₹11,509 Cr	₹3,862 Cr	₹2,138 Cr	₹5,836 Cr -67%
Total Assets	₹28,080 Cr	₹1.09L Cr	₹42,496 Cr	₹44,312 Cr	₹65,198 Cr -57%
EPS	₹46.35	₹47.8	₹48.03	₹63.92	₹53.25 -13%
Book Value per Share	₹394.87	₹348.31	₹426.24	₹247.86	₹340.8 +16%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.